Mesenchymal stem cell

Inhibition of adipogenic differentiation of bone marrow mesenchymal stem cells by erythropoietin via activating ERK and P38 MAPK

G. X. Liu, Zhu, J. C., Chen, X. Y., Zhu, A. Z., Liu, C. C., Lai, Q., and Chen, S. T., Inhibition of adipogenic differentiation of bone marrow mesenchymal stem cells by erythropoietin via activating ERK and P38 MAPK, vol. 14, pp. 6968-6977, 2015.

We examined whether erythropoietin (EPO) can inhibit adipogenic differentiation of mesenchymal stem cells (MSCs) in the mouse bone marrow and its underlying mechanism. We separated and extracted mouse bone marrow MSCs and induced adipogenic differen­tiation using 3-isobutyl-1-methylxanthine, insulin, and dexamethasone. Different concentrations of EPO were added to the cells and observed by Oil Red O staining on the 20th day to quantitatively analyze the degree of cell differentiation.

Effects of rifampicin on osteogenic differentiation and proliferation of human mesenchymal stem cells in the bone marrow

Z. Zhang, Wang, X., Luo, F., Yang, H., Hou, T., Zhou, Q., Dai, F., He, Q., and Xu, J., Effects of rifampicin on osteogenic differentiation and proliferation of human mesenchymal stem cells in the bone marrow, vol. 13, pp. 6398-6410, 2014.

This study was designed to investigate the effect of different concentrations of rifampicin on osteogenic differentiation and proliferation of mesenchymal stem cells (MSCs) in human bone marrow. Rifampicin treatment at 0, 4, 8, 16, 32, 64, and 128 mg/mL was applied throughout the whole process, from stromal cells purified from human bone marrow to differentiated bone cells. The effect of rifampicin on MSC proliferation was determined using the MTT assay.

Subscribe to Mesenchymal stem cell